RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
 - EconoTimes)
NEW ORLEANS, Sept. 08, 2017 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 24, 2017 to file lead plaintiff applications in a securities class action lawsuit against PetMed Express, Inc. (NASDAQ:PETS), if they purchased the Company’s securities between May 8, 2017, and August 23, 2017, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of Florida.
Get Help
PetMed Express investors should visit us at https://www.claimsfiler.com/cases/view-petmed-express-inc-securities-litigation-1 or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
PetMed Express and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On August 23, 2017, it was revealed through a comprehensive report issued by Aurelius Value entitled “PetMed: Exploiting America’s Opioid Epidemic” that PetMed Express had targeted its products, painkillers especially addictive synthetic opiates, to opioid users through the aggressive use of Google ads and other online marketing services, potentially facilitating the abuse of opiates as “human crossover painkillers.”
On this news, the price of PetMed Express shares plummeted.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
